Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population

Clinical Ophthalmology

Volumn 10, Issue , 2016, Pages 757-764

  Perera, Shamira A ^a,b,c   Ting, Daniel S W ^a,b   Nongpiur, Monisha E ^a,b,c   Chew, Paul T ^c   Aquino, Maria Cecilia D ^c   Sng, Chelvin C A ^c   Ho, Sue Wei ^a,b   Aung, Tin ^a,b,c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Asian; Bioresorbable; Glaucoma; Ocular hypertension; Punctum plug; Travoprost

Indexed keywords

TRAVOPROST;

ADULT; AGED; ARTICLE; ASIAN; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIPHORA; EVENING DOSAGE; EYE PAIN; FEASIBILITY STUDY; FEMALE; FOREIGN BODY REACTION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MEDICATION COMPLIANCE; MORNING DOSAGE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PRURITUS; PUNCTAL PLUG; SUSTAINED RELEASE FORMULATION;

EID: 84964762539     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S102181     Document Type: Article

References (11)

1. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57-S68.
2. Mansouri K, Iliev ME, Rohrer K, Shaarawy T. “Compliance and knowledge about glaucoma in patients at tertiary glaucoma units.” Int Ophthalmol. 2011;31:369-376.
3. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the glaucoma and adherence and persistency study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052-5057.
4. Quek DT, Ong GT, Perera SA, Lamoureux EL, Aung T. Persistence of patients receiving topical glaucoma monotherapy in an Asian population. Arch Ophthalmol. 2011;129:643-648.
5. Fiscella RG, Lee J, Davis EJ, Walt J. Cost of illness of glaucoma: a critical and systematic review. Pharmacoeconomics. 2009;27:189-198.
6. Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535-540.
7. Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clin Ophthalmol. 2015;9:633-643.
8. Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2007;1: 11-24.
9. Anderson DR, Patella VM. Automated Static Perimetry. 2nd ed. Vol 363. St Louis, MO: Mosby; 1999.
10. Honrubia F, García-Sánchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogs in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. Br J Ophthalmol. 2009;93:316-321.
11. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.